2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

@article{Stuart20112010GC,
  title={2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference},
  author={Gavin Stuart and Henry C Kitchener and Monica Bacon and Andreas Dubois and Michael L. Friedlander and Jonathan A. Ledermann and Christian Marth and Tate Thigpen and Edward Lloyd Trimble},
  journal={International Journal of Gynecologic Cancer},
  year={2011},
  volume={21},
  pages={750 - 755}
}
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. This report provides the outcomes from the Fourth Ovarian Cancer Consensus Conference. 

SEOM Clinical Guideline in ovarian cancer (2016)

TLDR
The aim of this guideline is to summarize the current evidence and to give evidence-based recommendations for clinical practice.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas

Abstract Low-grade serous ovarian cancer is a recently described histological subtype of ovarian cancer that is clinically and molecularly distinct from the 4 other main histological subtypes

The Role of Chemotherapy in Recurrent Ovarian Cancer

TLDR
There is no universally accepted consensus on the surveillance of ovarian cancer, but if the main clinical guidelines are reviewed, they can find similar recommendations for follow-up for patients with ovarian cancer after chemotherapy treatment.

Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER‐2 cohort study

To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach.

SEOM guideline in ovarian cancer 2014

TLDR
A significant improvement in the knowledge of the molecular biology of the different histotypes of ovarian cancer will probably change standard of care in the forthcoming years.

Surgery for Relapsed Ovarian Cancer: When Should it Be Offered?

TLDR
Surgery in platinum-sensitive recurrent ovarian cancer might be beneficial if it results in complete resection of the disease, and clinical scores could help to identify suitable patients.

Patient preferences in advanced or recurrent ovarian cancer

The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment‐related side effects, and progression‐free survival (PFS) relevant to choosing a

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo, Japan, in November 2015 are reported.
...

References

SHOWING 1-10 OF 15 REFERENCES

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

  • A. du BoisM. Quinn U. Wagner
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
2004 consensus statements on the management of ovarian cancer : final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004.

This document reports the history of the two previous ovarian cancer consensus meetings and the scope and methodology of the 3rd International Ovarian Cancer Consensus Conference, which was held by

Advanced epithelial ovarian cancer: 1998 consensus statements.

Advanced epithelial ovarian cancer: 1993 consensus statements.

  • D. AllenJ. Baak J. Dauplat
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 1993
TLDR
This article reports on the statements written by the chairmen and approved by the consensus group, which achieved consensus on a number of issues with implications for standard practice and for research.

Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

  • R. BurgerM. Brady S. Liang
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
This study demonstrates that front-line treatment of EOC, PPC, and FTC patients with CT plus concurrent and maintenance BEV prolongs PFS, the first anti-angiogenic agent to demonstrate benefit in this population.

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

TLDR
Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.

Oropharyngeal cancer, human papilloma virus, and clinical trials.

  • D. Rischin
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
It is learned that the regimen of docetaxel, cisplatin, and fluorouracil (TPF) improves overall survival when followed by radiation alone or radiation and weekly low-dose carboplatin, which does not seem to be a significant difference between the two.

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

TLDR
Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment, while survival in patients with optimally debulked stage III ovarian cancer improved.

Esophageal carcinoma in a 16-year-old girl 8 years after gastrotomy.

TLDR
A 16-year-old girl presented with progressively increasing dysphagia for a period of 2.5 months, having difficulty in swallowing solid food along with feeling of food getting stuck in the retrosternal region and being able to take solid food without difficulty.